We are live on
!
Find out more
WC
Westhampton Capital Portfolio holdings
AUM
$241M
1-Year Est. Return
38.64%
This Fund
S&P 500
This Quarter
Est. Return
+5.94%
1 Year Est. Return
+38.64%
3 Year Est. Return
+95.59%
5 Year Est. Return
+130.02%
10 Year Est. Return
–
AUM
$145M
AUM Growth
+$10.7M
(+8%)
Cap. Flow
+$4.18M
Cap. Flow
% of AUM
2.89%
Top 10 Holdings %
Top 10 Hldgs %
35.85%
Holding
111
New
8
Increased
34
Reduced
33
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ANAT
American National Group, Inc. Common Stock
ANAT
|
+$910K |
| 2 |
Qualcomm
QCOM
|
+$567K |
| 3 |
AbbVie
ABBV
|
+$425K |
| 4 |
Chubb
CB
|
+$410K |
| 5 |
Eli Lilly
LLY
|
+$336K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kraft Heinz
KHC
|
+$305K |
| 2 |
iShares Biotechnology ETF
IBB
|
+$202K |
| 3 |
Apple
AAPL
|
+$196K |
| 4 |
The Greenbrier Companies
GBX
|
+$158K |
| 5 |
Procter & Gamble
PG
|
+$104K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Staples | 23.13% |
| 2 | Industrials | 22.31% |
| 3 | Technology | 16.38% |
| 4 | Consumer Discretionary | 8.71% |
| 5 | Healthcare | 7.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Gilead Sciences
GILD
$162B
| $275K | 0.19% |
4,260
-200
| -4% | -$12.9K |
|
|
102
The Greenbrier Companies
GBX
$1.56B
| $236K | 0.16% |
5,000
-3,700
| -43% | -$158K |
|
103
TransDigm Group
TDG
$71.9B
| $236K | 0.16% |
402
| – | – |
|
104
US Bancorp
USB
$98.9B
| $233K | 0.16% |
+4,206
| New | +$210K |
|
105
MetLife
MET
$61.2B
| $208K | 0.14% |
+3,425
| New | +$189K |
|
|
ATCO
106
DELISTED
Atlas Corp.
ATCO
| $163K | 0.11% |
11,961
-2,000
| -14% | -$25.6K |
|
107
FNB Corp
FNB
$6.71B
| $132K | 0.09% |
10,383
| – | – |
|
|
NMCI
108
DELISTED
Navios Maritime Containers L.P. Common Units
NMCI
| $129K | 0.09% |
+14,000
| New | +$96.3K |
|
|
PEI
109
DELISTED
Pennsylvania Real Estate Investment Trust
PEI
| $29K | 0.02% |
1,000
| – | – |
|
|
110
iShares Biotechnology ETF
IBB
$9.44B
| – | – |
-1,335
| Closed | -$202K |
|
|
BMY.RT
111
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| – | – |
-11,150
| Closed | -$8K |
|
Similar funds
PFWA
SIM
AA
TTA
RS
DCM
GL
DO
Westhampton Capital's Q1 2021 Portfolio in Review
As of Q1 2021, Westhampton Capital held 111 positions worth $145M, up 8% from $134M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Westhampton Capital's Q1 2021 filing shows 8 new, 34 increased, 33 reduced and 2 closed positions. Its largest new stake was American National Group, Inc. Common Stock: 9,335 shares worth $1.01M. The largest sale was Kraft Heinz, an estimated $305K.
By sector, the portfolio is most concentrated in Consumer Staples at 23% of assets, down from 26% a quarter earlier, followed by Industrials and Technology.
- Westhampton Capital's largest Q1 2021 buy was American National Group, Inc. Common Stock: 9,335 shares worth $1.01M.
- Westhampton Capital added most to Qualcomm in Q1 2021, an estimated $567K increase.
- Westhampton Capital's biggest Q1 2021 reduction was Kraft Heinz, cutting an estimated $305K.
- Westhampton Capital fully exited iShares Biotechnology ETF in Q1 2021, selling an estimated $202K.
- Westhampton Capital's ten largest holdings make up 36% of its $145M portfolio in Q1 2021.
- Westhampton Capital opened 8 new positions and closed 2 in Q1 2021.
- Westhampton Capital's portfolio value rose 8% quarter-over-quarter to $145M.
Based on Westhampton Capital's 13F filing for Q1 2021, filed 11 May 2021.